Recombinant monoclonal antibodies (mAbs) are one of today's most successful therapeutic
classes in inflammatory diseases and oncology. A wider accessibility and implementation …

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptors
TRAILR1/death receptor 4 (DR4) and TRAILR2/DR5 trigger cell death in many cancer cells …

Antibody-based immune therapies targeting the T-cell checkpoint molecules CTLA-4 and
PD-1 have affected cancer therapy. However, this immune therapy requires complex …

Combining exquisite specificity and high antigen-binding affinity, intrabodies have been
used as a biotechnological tool to interrupt, modulate, or define the functions of a wide range …

Metastatic spread in Ewing sarcomas (ES) is frequent and haematogenous. G‐protein
coupled receptor 64 (GPR64), an orphan receptor with normal expression restricted to …

Gene therapy involves the transfer of genetic information to a target cell to facilitate the
production of therapeutic proteins and is now a realistic prospect as a cancer treatment …

Tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) induces apoptosis in a
variety of tumour cells, but not in most normal cells, and has attracted considerable attention …

It is well known that tumor necrosis factor-related apoptosis inducing ligand receptor 1 or 2
(DR4/DR5) is specifically expressed in various tumor cells, but less or no expression in most …

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is capable of
selectively inducing apoptosis of cancer cells, is a potential targeted drug for cancer therapy …

Background The current treatments for hepatocellular carcinoma (HCC) are poor,
particularly for metastatic HCC. Intraportal transfusion of adeno‐associated virus (AAV) …